Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.
Aim(s): The present study aims to compare the antitumor efficacy of apatinib with that of the standard PNET drug sunitinib in our subcutaneous and liver metastasis models of insulinoma and non-functional PNET.
Materials and methods: The antitumor potential of apatinib was evaluated in INR1G9-represented non-functional PNET and INS-1-represented insulinoma subcutaneous xenograft models and liver metastasis models. Tumor volume, angiogenesis and hypoxic area formation were analyzed. Cytotoxicity of apatinib on tumor cells was measured by using CCK-8 in vitro.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Shan Wu
To read results and conclusion, please login ...
Further abstracts you may be interested in